Literature DB >> 22415705

Treatment of focal dystonia.

Amit Batla1, Maria Stamelou, Kailash P Bhatia.   

Abstract

OPINION STATEMENT: Dystonia is characterized by repetitive twisting movements or abnormal postures due to involuntary muscle activity. When limited to a single body region it is called focal dystonia. Examples of focal dystonia include cervical dystonia (neck), blepharospasm (eyes), oromandibular dystonia, focal limb dystonia, and spasmodic dysphonia, which are discussed here. Once the diagnosis is established, the therapeutic plan is discussed with the patients. They are informed that there is no cure for dystonia and treatment is symptomatic. The main therapeutic option for treating focal dystonias is botulinum toxin (BoNT). There have been several attempts to characterize the procedure, the type of toxin, dosage, techniques, and combination with physical measures in each of the focal dystonia forms. The general treatment principles are similar. The affected muscles are injected at muscle sites based on evidence and experience using standard dosages based on the type of toxin used. The injections are repeated after 3 to 6 months based on the individual response duration. In the uncommon event of nonresponse with BoNT, the dose and site are reassessed. Oral drug treatment could be considered as an additional option. Once the condition is thought to be medically refractory, the opinion from the deep brain stimulation (DBS) team for the suitability of the patient for DBS is taken. The successful use of DBS in cervical dystonia has led to increased acceptance for trial in other forms of focal dystonias. DBS surgery in focal dystonias other than cervical is, however, still experimental. The patients may be offered the surgery with adequate explanation of the risks and benefits. Patient education and directing the patients towards dystonia support groups and relevant websites that provide scientific information may be useful for long-term compliance and benefit.

Entities:  

Year:  2012        PMID: 22415705     DOI: 10.1007/s11940-012-0169-6

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  80 in total

1.  Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia.

Authors:  C L Comella; J Jankovic; K M Shannon; J Tsui; M Swenson; S Leurgans; W Fan
Journal:  Neurology       Date:  2005-11-08       Impact factor: 9.910

2.  Localizing muscles for botulinum toxin treatment of focal hand dystonia.

Authors:  C Geenen; E Consky; P Ashby
Journal:  Can J Neurol Sci       Date:  1996-08       Impact factor: 2.104

3.  EFNS guidelines on diagnosis and treatment of primary dystonias.

Authors:  A Albanese; F Asmus; K P Bhatia; A E Elia; B Elibol; G Filippini; T Gasser; J K Krauss; N Nardocci; A Newton; J Valls-Solé
Journal:  Eur J Neurol       Date:  2011-01       Impact factor: 6.089

4.  Effect of muscle activity immediately after botulinum toxin injection for writer's cramp.

Authors:  R Chen; B I Karp; S R Goldstein; W Bara-Jimenez; Z Yaseen; M Hallett
Journal:  Mov Disord       Date:  1999-03       Impact factor: 10.338

5.  Cervical dystonia: clinical findings and associated movement disorders.

Authors:  J Jankovic; S Leder; D Warner; K Schwartz
Journal:  Neurology       Date:  1991-07       Impact factor: 9.910

6.  Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial.

Authors:  J W Brans; R Lindeboom; J W Snoek; M J Zwarts; T W van Weerden; E R Brunt; J J van Hilten; W van der Kamp; M H Prins; J D Speelman
Journal:  Neurology       Date:  1996-04       Impact factor: 9.910

7.  DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A--Dysport and Botox--assuming a ratio of 4:1.

Authors:  C Sampaio; J J Ferreira; F Simões; M J Rosas; M Magalhães; A P Correia; A Bastos-Lima; R Martins; A Castro-Caldas
Journal:  Mov Disord       Date:  1997-11       Impact factor: 10.338

8.  Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study.

Authors:  J Jankovic
Journal:  Ann Neurol       Date:  1982-01       Impact factor: 10.422

9.  Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Authors:  D M Simpson; A Blitzer; A Brashear; C Comella; R Dubinsky; M Hallett; J Jankovic; B Karp; C L Ludlow; J M Miyasaki; M Naumann; Y So
Journal:  Neurology       Date:  2008-05-06       Impact factor: 9.910

10.  Double-blind trial of botulinum toxin for treatment of focal hand dystonia.

Authors:  R Cole; M Hallett; L G Cohen
Journal:  Mov Disord       Date:  1995-07       Impact factor: 10.338

View more
  8 in total

1.  Ixcellence Network®: an international educational network to improve current practice in the management of cervical dystonia or spastic paresis by botulinum toxin injection.

Authors:  Klemens Fheodoroff; Roongroj Bhidayasiri; Luis Jorge Jacinto; Tae Mo Chung; Kailash Bhatia; Therese Landreau; Carlo Colosimo
Journal:  Funct Neurol       Date:  2017 Apr/Jun

2.  The role of the trigeminal sensory nuclear complex in the pathophysiology of craniocervical dystonia.

Authors:  Lynley Bradnam; Christine Barry
Journal:  J Neurosci       Date:  2013-11-20       Impact factor: 6.167

3.  Abnormal dorsal premotor-motor inhibition in writer's cramp.

Authors:  Sarah Pirio Richardson; Sandra Beck; Barbara Bliem; Mark Hallett
Journal:  Mov Disord       Date:  2014-04-07       Impact factor: 10.338

4.  Pallidal stimulation for medically intractable blepharospasm.

Authors:  Kazumichi Yamada; Naoki Shinojima; Tadashi Hamasaki; Jun-ichi Kuratsu
Journal:  BMJ Case Rep       Date:  2016-03-31

5.  Temporomandibular disorder-related characteristics and treatment outcomes in Oromandibular Dystonia patients in two different clinical settings: A cross-sectional study.

Authors:  Asha Sude; Joseph Matsumoto; Shanti Kaimal; Ashley Petersen; Donald R Nixdorf
Journal:  J Oral Rehabil       Date:  2021-03-07       Impact factor: 3.837

6.  Repetitive transcranial magnetic stimulation in cervical dystonia: effect of site and repetition in a randomized pilot trial.

Authors:  Sarah Pirio Richardson; Sule Tinaz; Robert Chen
Journal:  PLoS One       Date:  2015-04-29       Impact factor: 3.240

7.  Comparable Botulinum Toxin Outcomes between Primary and Secondary Blepharospasm: A Retrospective Analysis.

Authors:  Daniel Martinez-Ramirez; Juan C Giugni; Erin Hastings; Aparna Wagle Shukla; Irene A Malaty; Michael S Okun; Ramon L Rodriguez
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2014-12-15

Review 8.  Sports-Related Dystonia.

Authors:  Abhishek Lenka; Joseph Jankovic
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2021-12-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.